The risk of alopecia areata and other related autoimmune diseases in patients with sleep disorders: a Korean population–based retrospective cohort study

Seo, Hyun-Min; Kim, Tae Lim; Kim, Joung Soo

doi:10.1093/sleep/zsy111

Cited by 30 publications

(49 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dementia was further classified as Alzheimer disease (ICD‐10 codes F00 and G30), vascular dementia (ICD‐10 code F01), and other dementia (ICD‐10 codes F02, F03, and G31), and the definition of dementia included inpatients as well as outpatients in the present data. This study used sleep disorders as independent variable, and the sleep disorders were measured by F51 (sleep disorders not due to a substance or known physiological condition) or G47 (sleep disorders) under ICD‐10 codes as primary diagnosis 20 . Table S1 presents the number of incidents of dementia according to subtypes of sleep disorders; 138 participants with sleep disorders were diagnosed with dementia during the follow‐up period among 1059 subjects with sleep disorders, and insomnia accounted for approximately 76% of all sleep disorders in the present study.…”

Section: Methodsmentioning

confidence: 99%

Sleep disorders and risk of dementia in patients with new‐onset type 2 diabetes: A nationwide population‐based cohort study

Jin

Choi

2020

Journal of Diabetes

View full text Add to dashboard Cite

Background: This study examined the relationship between sleep disorders and the risk of dementia in patients with newly diagnosed type 2 diabetes. Methods: This study used the Korean Health Screening Cohort data and included 39 135 subjects aged ≥40 years with new-onset type 2 diabetes between 2004 and 2007, with follow-up throughout 2013. Sleep disorders were measured by F51(sleep disorders not due to a substance or known physiological condition) or G47(sleep disorders) under International Classification of Diseases, Tenth Revision (ICD-10) codes as a primary diagnosis, and the adjusted hazard ratio (AHR) and 95% CI of all-cause dementia, Alzheimer disease, vascular dementia, and other dementia were estimated using multivariable Cox proportional hazards regression models. Results: In the patients with type 2 diabetes with an age range between 42 and 84 years (M = 57.8, SD = 9.5), this study identified 2059 events of dementia during an average follow-up time of 5.7 years. In patients with type 2 diabetes, subjects with sleep disorders were associated with an increased risk of all-cause dementia (AHR, 1.46; 95% CI, 1.19-1.80), Alzheimer disease (AHR, 1.39; 95% CI, 1.02-1.88), and other dementia (AHR, 1.69; 95% CI, 1.23-2.31) compared to those without sleep disorders. Men (AHR, 1.93; 95% CI, 1.42-2.62) and older adults (AHR, 1.70; 95% CI, 1.35-2.15) with sleep disorders were associated with an increased risk of dementia than their counterparts without sleep disorders among patients with type 2 diabetes. Conclusions: These findings suggest that sleep disorders are significantly associated with an increased risk of dementia in patients with new-onset type 2 diabetes.

show abstract

Section: Methodsmentioning

confidence: 99%

Sleep disorders and risk of dementia in patients with new‐onset type 2 diabetes: A nationwide population‐based cohort study

Jin

Choi

2020

Journal of Diabetes

View full text Add to dashboard Cite

show abstract

“…The survival length was estimated in days, and all study participants underwent follow-up examination until the occurrence of either of the following three outcomes: incidence of CVD or mortality, withdrawal from the medical security system, or the end of 2013, whichever occurred first. We utilized sleep disturbance as independent variable and estimated the same using the G47 (sleep disorders) or F51 (sleep disorders not due to a substance or known physiological condition) under ICD-10 codes as a primary diagnosis [20].…”

Section: Measurementmentioning

confidence: 99%

Association of sleep disturbance with risk of cardiovascular disease and all-cause mortality in patients with new-onset type 2 diabetes: data from the Korean NHIS-HEALS

Choi

2020

Cardiovasc Diabetol

View full text Add to dashboard Cite

Background: Sleep disturbance has been significantly associated with the incidence of cardiovascular disease (CVD) in the general population. However, despite the common prevalence of sleep disturbance in patients with type 2 diabetes, its relationship with the risk of CVD remains unclear. Here, we have examined the association of sleep disturbance with the incidence of all CVD and all-cause mortality in patients with newly-diagnosed type 2 diabetes. Methods: We used the Korean National Health Insurance Service-Health Screening Cohort data and included 36,058 patients with new-onset type 2 diabetes aged ≥ 40 years between 2004 and 2007, along with follow-up examinations to 2013. We used the ICD-10 code to measure sleep disturbance as a primary diagnosis and the multivariable Cox proportional hazards regression models to estimate the adjusted hazard ratio (AHR) and 95% confidence interval (CI) of all CVD, coronary heart disease (CHD), stroke, and all-cause mortality. Results: We identified 6897 cases of all CVD (CHD, n = 4138; stroke, n = 2759) and 2890 events of all-cause mortality during a mean follow-up period of 7.0 years. Sleep disturbance was associated with an increased risk of All CVD (AHR, 1.24; 95% CI, 1.06-1.46), CHD events (AHR, 1.24; 95% CI, 1.00-1.53), and all-cause mortality (AHR, 1.47; 95% CI, 1.15-1.87) in patients with new-onset type 2 diabetes. Furthermore, women (AHR, 1.33; 95% CI, 1.06-1.67) and middle-aged adults (AHR, 1.29; 95% CI, 1.02-1.64) with sleep disturbance had a significantly increased risk of CVD than those without; contrarily, men (AHR, 1.45; 95% CI, 1.09-1.95) and older adults (AHR, 1.51; 95% CI, 1.15-1.99) with sleep disturbance were associated with a significantly increased risk of all-cause mortality than those without. Conclusions: Our findings suggest that sleep disturbance is significantly associated with an increased risk of CVD and all-cause mortality in patients with new-onset type 2 diabetes.

show abstract

“…[ 33 34 ] Interestingly, nutritional deficiencies, including Vitamin D and iron are also more common in AA patients[ 33 35 ] as are sleep disorders. [ 36 ]…”

Section: Physical Co-morbiditiesmentioning

confidence: 99%

Cumulative life course impairment of alopecia areata

et al. 2020

View full text Add to dashboard Cite

Alopecia areata (AA), an unpredictable, nonscarring hair loss, is commonly perceived as a cosmetic, rather than medical, concern. However, substantial evidence exists describing the negative impact on quality of life, as the disease affects patients personally, socially, financially, and physically. Over time, the cumulative disability may perpetuate poor confidence, social disconnection, negative coping strategies, and failure to achieve a full life potential. Here, we describe the cumulative life course impairment (CLCI) of AA by examining the complex interaction of (1) stigmatization, (2) physical and psychiatric comorbidities, and (3) coping strategies. The model aggregates existing cross-sectional data, which have previously captured disease burden only as snapshots in time. Thus, by examining cumulative effects, the CLCI model serves as a proxy for longitudinal data to better describe life course epidemiology of the disease.

show abstract

The risk of alopecia areata and other related autoimmune diseases in patients with sleep disorders: a Korean population–based retrospective cohort study

Abstract: This study demonstrated that sleep disorder is an independent risk factor for alopecia areata, especially in individuals under the age of 45 years old.

Cited by 30 publications

References 28 publications

Sleep disorders and risk of dementia in patients with new‐onset type 2 diabetes: A nationwide population‐based cohort study

Sleep disorders and risk of dementia in patients with new‐onset type 2 diabetes: A nationwide population‐based cohort study

Association of sleep disturbance with risk of cardiovascular disease and all-cause mortality in patients with new-onset type 2 diabetes: data from the Korean NHIS-HEALS

Cumulative life course impairment of alopecia areata

Contact Info

Product

Resources

About